BOULDER, Colo., Aug. 14, 2019 /PRNewswire/ — Digipath, Inc. (OTCQB: DIGP), a service-oriented independent testing laboratory, data analytics and formulation firm focused on the developing cannabis and hemp markets, is pleased to announce that its GroSciences division has successfully completed preliminary validation testing on its patent pending all-natural, plant-derived pesticide, TERPO+ Broadspectrum. The product could potentially serve an enormous market by protecting cannabis plants against colonization by microorganisms. The testing has also shown that TERPO+ Broadspectrum acts as a treatment for the elimination of microbial bioburden on cannabis and hemp flowers. Microorganisms and microbial bioburden are the largest single factor in cannabis crop loss.
TERPO+ Broadspectrum has been developed by GroSciences as a natural, non-synthetic, pest decontamination product for the cannabis and hemp cultivation industry. Recent cannabis flower experiments have demonstrated the effectiveness of the TERPO+ Broadspectrum formulation in rendering cannabis flower samples to be within microbial testing limits in most states. TERPO+ Broadspectrum treatment reduced the measured CFU/g by 91% compared to untreated samples and early testing results suggest TERPO+ Broadspectrum may be an effective microbial solution for hemp and cannabis flower.
“The early results for GroSciences’ TERPO+ Broadspectrum are remarkable,” stated Dr. Cindy Orser, Chief Science Officer, Digipath Inc. “In our preliminary R & D validation test, we successfully treated a sample that had previously failed a state microbial test, and after treatment, the plant matter tested at a passing limit. We’re very excited to move into phase 2 testing.”
“A product like TERPO+ Broadspectrum that can effectively treat plant material and help make it into sellable product has great potential,” added Denkin. “We will continue to move forward with product testing and development and will seek to introduce it to the market as soon as we can.”
About Digipath, Inc. (OTCQB: DIGP)
Digipath, Inc., supports the cannabis industry’s best practices for reliable testing, data acquisition, formulations, and new canna-tech to the cannabis industry.
Digipath Labs provides pharmaceutical-grade analysis and testing to the cannabis industry to ensure producers, consumers and patients know exactly what is in the cannabis they ingest and to help maximize the quality of its client’s products through analysis, research, development, and standardization.
GroSciences delivers a new approach to canna-tech product development in the cannabis industry and provides for true cannabis cultivar identification for hemp and cannabis operations and law enforcement agencies.
Information about Forward-Looking Statements
This press release contains “forward-looking statements” that include information relating to future events. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to: the Company’s need for additional funding, the demand for the Company’s products, governmental regulation of the cannabis industry, the Company’s ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company’s liquidity and financial strength to support its growth, and other risks that may be detailed from time-to-time in the Company’s filings with the United States Securities and Exchange Commission. For a more detailed description of the risk factors and uncertainties affecting Digipath, please refer to the Company’s recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Investor Relations & Financial Media
Integrity Media
team@integritymedia.com
Toll Free: (888) 216-3595
www.IntegrityMedia.com
SOURCE Digipath, Inc.
